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Abstract
Background: Tazarotene-induced gene 1 (TIG1) is a retinoid-inducible type II tumour suppressor gene. The B
isoform of TIG1 (TIG1B) inhibits growth and invasion of cancer cells. Expression of TIG1B is frequently
downregulated in various cancer tissues; however, the expression and activities of the TIG1A isoform are yet to be
reported. Therefore, this study investigated the effects of the TIG1A and TIG1B isoforms on cell growth and gene
expression profiles using colon cancer cells.
Methods: TIG1A and TIG1B stable clones derived from HCT116 and SW620 colon cancer cells were established
using the GeneSwitch system; TIG1 isoform expression was induced by mifepristone treatment. Cell growth was
assessed using the WST-1 cell proliferation and colony formation assays. RNA interference was used to examine the
TIG1 mediating changes in cell growth. Gene expression profiles were determined using microarray and validated
using real-time polymerase chain reaction, and Western blot analyses.
Results: Both TIG1 isoforms were expressed at high levels in normal prostate and colon tissues and were
downregulated in colon cancer cell lines. Both TIG1 isoforms significantly inhibited the growth of transiently
transfected HCT116 cells and stably expressing TIG1A and TIG1B HCT116 and SW620 cells. Expression of 129 and 55
genes was altered upon induction of TIG1A and TIG1B expression, respectively, in stably expressing HCT116 cells.
Of the genes analysed, 23 and 6 genes were upregulated and downregulated, respectively, in both TIG1A and
TIG1B expressing cells. Upregulation of the G-protein-coupled receptor kinase 5 (GRK5) was confirmed using real-
time polymerase chain reaction and Western blot analyses in both TIG1 stable cell lines. Silencing of TIG1A or GRK5
expression significantly decreased TIG1A-mediated cell growth suppression.
Conclusions: Expression of both TIG1 isoforms was observed in normal prostate and colon tissues and was
downregulated in colon cancer cell lines. Both TIG1 isoforms suppressed cell growth and stimulated GRK5
expression in HCT116 and SW620 cells. Knockdown of GRK5 expression alleviated TIG1A-induced growth
suppression of HCT116 cells, suggesting that GRK5 mediates cell growth suppression by TIG1A. Thus, TIG1 may
participate in the downregulation of G-protein coupled signaling by upregulating GRK5 expression.
Keywords: RARRES1 TIG1, GRK5, microarray, colon cancer cells, tumour suppressor
* Correspondence: jiang.shunyuan@gmail.com
† Contributed equally
2Department of Research, Buddhist Tzu Chi General Hospital Taipei Branch,
289 Jianguo Rd, Sindian District, New Taipei City, 231 Taiwan
Full list of author information is available at the end of the article
Wu et al. BMC Cancer 2011, 11:175
http://www.biomedcentral.com/1471-2407/11/175
© 2011 Wu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
The tazarotene-induced gene 1 (TIG1), also known as
retinoic acid receptor responder 1 (RARRES1), is a reti-
noic acid receptor-responsive gene that was isolated
from skin raft cultures treated with the synthetic reti-
noid, tazarotene [1]. The TIG1 gene, located on chro-
mosome 3q25.32, is expressed in most normal tissues
[2]. Loss of chromosome 3q heterozygocity has been
reported in cancer tissues [3-5], while downregulation of
TIG1 expression through promoter hypermethylation
has been reported to occur in various carcinomas,
including nasopharyngeal, esophageal, prostate, and
colon [5-11].
The TIG1 gene encodes a transmembrane protein that
contains a conserved latexin domain as well as a glyco-
sylation signal and a hyaluronic acid-binding motif [1].
The protein shares 30% sequence similarity to the car-
boxypeptidase inhibitor, latexin, that regulates the size
of the haematopoietic stem cell population [12]. How-
ever, it remains unknown whether TIG1 acts as a pro-
tease inhibitor. Expression of TIG1 is induced in
differentiated psoriatic lesions and Caco-2 colon cancer
cells treated with pro-differentiating agents, such as
AGN1901683, a synthetic retinoid [1], or vitamin D3
[13]. In addition, TIG1 may regulate cellular differentia-
tion. Indeed, the expression of TIG1 is closely associated
with the differentiation of colorectal adenocarcinoma
[14] and mesenchymal stem cells derived from adipo-
cytes [15]. In the prostate, TIG1 expression is progres-
sively lost from benign tissues to malignant lesions,
while the ectopic expression of TIG1 suppresses cellular
growth in vitro [7,10] and in vivo [2]. Further, TIG1 has
been reported to be differentially expressed in sponta-
neously regressing melanomas in a MeLiM swine model
of melanoma [16]. Finally, TIG1 expression suppresses
the invasion of prostate cancer cells [2]. Conversely,
knock-down of TIG1 expression increases invasion of
Epstein-Barr virus-infected nasopharyngeal carcinoma
cells [7]. Thus, TIG1 is a tumour suppressor that pre-
vents carcinogenesis in several tissue types. However,
the molecular mechanisms underlying the activities of
TIG1 on cell growth, invasion and differentiation have
not been reported.
According to information obtained from AceView,
there are 8 putative protein isoforms encoded by the
TIG1 gene [17]. Studies analysing the suppression of cell
growth and invasion by TIG1 have focused on the
TIG1B isoform [GenBank:NP_002879.2] that comprises
228 amino acids [2,7,10]; however, characterisation of
the expression and activity of the TIG1A isoform is yet
to be reported. The TIG1A isoform [GenBank:
NP_996846.1] contains 294 amino acids and shares the
same N-terminal 224 amino acid sequence as TIG1B. In
this study, we investigated the effects of both TIG1
isoforms on growth and gene expression profiles in
HCT116 colon cancer cells to test the hypothesis that
TIG1A also suppresses colon cell growth. To determine
the proteins associated with TIG1A- and TIG1B-related
growth of colon cancer cells, inducible stable cells that
expressed TIG1A or TIG1B protein isoforms in
HCT116 and SW620 colon cancer cells were established
using the GeneSwitch™ system [18]. In the GeneS-
witch™ system, a hybrid regulatory protein containing a
DNA binding domain from the yeast GAL4 protein, a
truncated ligand binding domain from the human pro-
gesterone receptor and an activation domain from the
human NF-kB protein is expressed in the pSwitch plas-
mid. The system allows the induction of TIG1A and
TIG1B expression in cells harboring the hybrid regula-
tory protein upon exposure to the synthetic progestin,
mifepristone (MFP). Gene expression profile changes
upon TIG1A and TIG1B expression were analysed by
microarray. G-protein-coupled receptor kinase 5
(GRK5), a serine/threonine kinase, which suppresses the
activation of ligand-activated G-protein-coupled recep-
tors (GPCRs) [19], was upregulated by both TIG1 iso-
f o r m s .T h ei m p o r t a n c eo fG R K 5o nT I G 1 - i n d u c e d
growth suppression was analysed using RNA
interference.
Methods
Construction of expression vectors
Constitutive expression vectors encoding myc and his-
tagged TIG1A (pTIG1A-myc) and TIG1B (pTIG1B-
myc) fusion proteins were constructed. The TIG1A and
TIG1B cDNA fragments were amplified from human
SC-M1 gastric cancer cells, obtained from Dr. C.-L.
Meng (National Defense Medical Center, Taipei, Tai-
wan), using TIG1A-specific primers (sense, 5’-CTC
TGAATTCCTGCGTCCATGCAGCCC-3’ and antisense,
5’-GCGCGGATCCGAAATTACTAAGCTCTG-3’)a n d
TIG1B-specific primers (sense, 5’-CTCTGAATTCC
TGCGTCCATGCAGCCC-3’ and antisense, 5’-CG
GACGGATCCGGTTTTTCTTACCCAC-3’). Amplified
cDNA fragments were digested with EcoRI and BamHI,
and then subcloned in-frame into the multicloning site
of the pcDNA3.1-myc-his A expression vector (Invitro-
gen, Carlsbad, CA, USA). To generate inducible TIG1A
and TIG1B expression plasmids (pTIG1A-V5 and
pTIG1B-V5, respectively), HindIII- and BamHI-digested
TIG1 cDNA fragments isolated from pTIG1A-myc or
pTIG1B-myc were cloned in-frame into the pGene-V5-
his B vector (Invitrogen).
Cell culture and transfection
HCT116 colon cancer cells were maintained in growth
medium consisting of McCoy’s5 Am e d i u m( B i o W e s t ,
Nuaille, France) supplemented with 25 mM HEPES,
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penicillin, 100 μg/mL streptomycin, and 10% fetal
bovine serum (FBS; Hyclone, Logan, Utah, USA) at 37°C
and 5% CO2. SW620 cells were maintained in growth
medium consisting of Leibovitz’s L15 medium (GIBCO
BRL, Grand island, NY, USA) supplemented with 25
mM HEPES, 26 mM NaHCO3, 2 mM L-glutamine, 100
units/mL penicillin, 100 μg/mL streptomycin, and 10%
FBS at 37°C without CO2. HT-29, LS174T, and SW480
colon cells were maintained in Dulbecco’s Modified
Essential Medium (GIBCO BRL) supplemented with
1 0 %F B S .C C - M 1 ,C C - M 2 ,C C - M 3 ,D L D - 1 ,a n d
COLO205 colon cells were maintained in RPMI med-
ium (GIBCO BRL) supplemented with 25 mM HEPES,
26 mM NaHCO3, 2 mM L-glutamine, 100 units/mL
penicillin, 100 μg/mL streptomycin, and 10% FBS at 37°
Ca n d5 %C O 2. Colon cancer cells were obtained from
Food Industry Research and Development Institute
(Sinju, Taiwan).
HCT116 cells plated in 6-cm culture dishes were
transfected with expression vectors using liposome-
mediated transfection. Briefly, plasmids or small inter-
fering RNAs (siRNAs) and lipofectamine (Invitrogen)
were diluted in Opti-MEM medium (GIBCO BRL) and
then mixed at room temperature for 15 min. The
nucleic acid-lipofectamine complexes were then added
to cells for 2.5 h at 37°C. Cells were then refreshed with
complete medium for 24 h at 37°C for further analysis.
Establishment of inducible TIG1 stable clones
I n d u c i b l eT I G 1s t a b l ec l o n e sw e r ee s t a b l i s h e du s i n gt h e
GeneSwitch system (Invitrogen) as previously described
with minor modifications [20]. Briefly, HCT116 cells pla-
ted in 10-cm dishes were first transfected with the pSwitch
expression vector (Invitrogen) that expressed the hybrid
regulatory protein using lipofectamine, and then selected
in hygromycin (400 μg/mL, Invitrogen)-containing med-
ium. Stable HCT116/Switch clones were selected by limit-
ing dilution and validated by analysing the induced
expression of b-galactosidase followed by the transfection
with pLacZ/V5 (Invitrogen) and then incubation with 10
nM MFP. HCT116/Switch cells that expressed the MFP-
dependent transactivator were selected for subsequent
transfection with pTIG1A-V5, pTIG1B-V5, or the control
vector (pGene-V5-his B). Stable cells were selected in
medium containing hygromycin and zeocin (125 μg/mL,
Invitrogen). Inducible expression of TIG1A and TIG1B
was validated by immunocytochemistry and Western blot
analyses. Stable clones were maintained in McCoy’s5 A
growth medium supplemented with hygromycin and zeo-
cin. Cells used for further experiments were plated in
medium without hygromycin and zeocin. Representative
inducible TIG1A (clone 2), TIG1B (clone 8), and control
(2G5) stable clones were selected for analysis.
Using similar methods, inducible TIG1A (clone 13),
TIG1B (clone 7), and control (clone 1) stable clones
were established in SW620 colon cancer cells. Stable
cells were maintained in L15 growth medium supple-
mented with 800 μg/mL hygromycin and 400 μg/mL
zeocin. Cells were monitored monthly for mycoplasma
contamination using the DNA intercalating dye, 4’6-dia-
midino-2-phenylindole (Sigma, St. Louis, MO, USA).
Analysis of cellular proliferation
HCT116 cells were seeded at 2 × 10
4 cells per well in
24-well plates overnight and then transfected with con-
stitutive TIG1A or TIG1B expression vector or control
vector for 48 h. WST-1 reagent (100 μL Roche Diagnos-
tics, Mannheim, Germany) was then added to the cells
for 4 h at 37°C. Absorbance at 450 and 650 nm was
assessed. The percentage of proliferative TIG1A or
TIG1B transfected cells relative to controls was defined
as [(A450-A650) of TIG1A or TIG1B transfected cells/
(A450-A650) of control transfected cells] × 100%. Alterna-
tively, control or TIG1 stable clones were plated over-
night in growth medium free of hygromycin and zeocin.
The cells were then incubated in growth medium con-
taining MFP (0.1 - 100 nM) or ethanol (0.1%) vehicle
for 48 h. The percentage of MFP-treated proliferative
cells relative to controls was defined as [(A450-A650)o f
MFP-treated cells/(A450-A650) of ethanol-treated cells] ×
100%. All experiments were performed in triplicate.
Colony formation assay
HCT116 cells were plated in 6-well dishes and trans-
fected with pTIG1A-myc, pTIG1B-myc expression vec-
tor, or control vector for 3 h after which they were
incubated in growth medium for 1 day. Cells were then
cultured in medium containing 1000 μg/mL G-418 for 8
days with medium changes performed every other day.
The number of colonies was determined using crystal
violet staining as described previously [21]. All experi-
ments were performed in triplicate.
Microarray analysis
Inducible TIG1A, TIG1B, and control stable HCT116
cell clones plated overnight in 10-cm dishes in growth
medium were stimulated with growth medium contain-
ing 5 nM MFP for 24 h. Cells were washed twice with
ice-cold PBS (3.2 mM Na2HPO4,0 . 5m MK H 2PO4,1 . 3
mM KCl, 135 mM NaCl, pH 7.4), detached by scraping
and isolated by centrifugation at 1500 × g for 5 min at
4°C. Three independent samples were collected for
microarray analysis.
Total RNA was extracted using the RNeasy system
(Qiagen, Valencia, CA, USA). The integrity of the RNA
was assessed using a 2100 Bioanalyzer (Agilent Technol-
ogies, Palo Alto, CA, USA). Integrity values exceeded
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was carried out according to the manufacturer’sp r o t o -
col (Affymetrix, Santa Clara, CA, USA). Briefly, cRNA
probes were prepared from 10 μg of total RNA using an
Affymetrix One Cycle cDNA synthesis kit (Affymetrix).
The biotinylated cRNA was subsequently fragmented
and hybridised to each array at 45°C for over 16 h.
cRNA was hybridised to the HGU133-2 plus whole gen-
ome GeneChip containing 54,675 transcripts. Quality
assessment was performed using the GeneChip Operat-
ing System 1.1.1 (Affymetrix) using global scaling to a
target signal of 500. Median background was 38.0 - 40.7.
Median scaling factors were 6.5 - 9.2, and noise values
ranged from 1.6 - 1.8. High overall array and RNA qual-
ity were confirmed.
Normalisation and statistical analysis
Gene expression data underwent secondary analysis
using the GeneSpring GX program (Agilent Technolo-
gies, Santa Clara, CA, USA). Briefly, gene expression
data from the microarray chips were rescaled (after pre-
liminary analysis) for a direct comparison between all
chips. Data were filtered based on both Detection Call
and Signal Log Ratio for comparisons between groups
(control and TIG1A or control and TIG1B). Data
declared “Absent” in all samples were filtered out. Sam-
ples had to be declared “Present” in at least 2 of 3 chips
within a group to be maintained within the set. The log
base 2.0 of the fold change was used as an additional fil-
ter. Filtered genes identified to be differentially
expressed by 2-fold or greater in 2 of 3 chips were ana-
lysed for functional gene clusters using GeneSpring. Sta-
tistical analyses were performed using one-way ANOVA
(P < 0.05) and t-tests. The program was used to deter-
mine functional clusters by statistical representation of
individual genes in specific categories relative to all
genes in the same category on the array. Signal path-
ways of differentially expressed genes were validated
using the Protein Analysis Through Evolution Relation-
ships (PANTHER™) protein classification system
(Applied Biosystems, Foster City, CA, USA). Original
microarray data have been deposited in the Gene
Expression Omnibus data bank (accession number:
GSE23882).
RNA isolation and quantitative real-time reverse
transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted using TRIZOL reagent (Invi-
trogen). cDNA was prepared by incubating a 20 μL mix-
ture containing 5 μg total RNA, 1 unit Moloney murine
leukemia virus (MuLV) reverse transcriptase (Invitro-
gen), 0.5 μg oligo-dT12-18 in 50 mM Tris-HCl, pH 8.3,
75 mM KCl, 4.25 mM MgCl2,0 . 5m Md N T P ,a n d1
unit RNaseout recombinant RNase inhibitor (Invitrogen)
at 37°C for 1 h. Real-time RT-PCR was performed using
the ABI prism 7900HT sequencer detector system
(Applied Biosystems) and Qiagen’s Quantitect SYBR
Green PCR kit (Qiagen) following the instructions pro-
vided. In brief, reaction mixtures (25 μlo ft o t a lv o l u m e )
containing 250 ng cDNA, gene-specific forward and
reverse primers (1 μM), and 12.5 μL of 2× Quantitect
SYBR Green PCR Master mix were cycled as follows: 1
cycle at 95°C for 10 min; 40 cycles at 95°C for 15 sec-
onds; and 60°C for 1 min. Negative controls without the
template were run in parallel to assess the overall speci-
ficity of the reaction. PCR primers used for amplification
included the following: beta-actin (sense, 5’-
TCCCTGGAGAAGAGCTACG-3’ and antisense, 5’-
GTAGTTTCGTGGATGCCACA-3’), TIG1 (sense, 5’-
CGTGGTCTTCAGCACAGAGCG-3’ and antisense, 5’-
CCCAAACGTCCCTCACCTTCC-3’), GRK5 (sense, 5’-
GACCACACAGACGACGACTTC-3’ and antisense, 5’-
CGTTCAGCTCCTTAAAGCATTC-3’), TIG1A (sense,
5’- CCGAGCCAACTTTCCTGCGTCC-3’ and antisense,
5’-CCCTGAGGAACCTGCTGGTGACTG-3’), TIG1B
(sense, 5’-CGAGCCAACTTTCCTGCGTC-3’ and anti-
sense, 5’-CTTGTGGCACAAGTTAATTTTCAGG-3’),
and TCF7 (sense, 5’-TCCAGAGCCCCTGGAGGACG-3’
and antisense, 5’-GGGCTGATTGGCCTTGTGCA-3’).
Relative TIG1A, TIG1B, TCF7, or GRK5 mRNA levels
in MFP-induced stable cells after normalisation to the
vehicle treated control cells were calculated as follows:
2
- ΔΔCT =2 / ( [ C T of TIG1A in MFP-treated cells]- [CT
of actin in MFP-treated cells])- ([CT of TIG1A in con-
trol cells]- [CT of actin in control cells]). All experi-
ments were performed in triplicate.
Relative expression of TIG1A and TIG1B in normal tis-
sues and colon cancer cell lines was determined using the
icycler system (Bio-Rad Laboratories, Hercules, CA, USA).
Total RNAs from normal tissues obtained from Clontech
Laboratories (Clontech, Palo Alto, CA, USA) and colon
cancer cells purified as described above were reverse tran-
scribed. Real time RT-PCR was performed in reaction
mixtures (20 μL total volume) containing 100 ng cDNA,
gene-specific forward and reverse primers (160 nM), and
10 μL2 ×i Q ™ SYBR
® Green Supermix (Bio-Rad). The
real-time cycler conditions were as follows: 1 cycle at 94°C
for 3 min and 40 cycles at 94°C for 30 seconds, 61°C for
30 seconds, and 72°C for 30 seconds. Primers used for
amplification were as follows: TIG1A (sense, 5’-
CCTGTCGCATTCACTTGGTCTG-3’ and antisense, 5’-
CGGAGG CTTCTTCTGGTGTCTG-3’), TIG1B (sense,
5’-TCTGAGACTCATCTGGGATT TG-3’ and antisense,
5’-CTTTGATTGTAACTCTT GTGGC-3’), and glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH; sense, 5’-
TCCATGCCATCACT GCCACCC-3’ and antisense, 5’-
GACGCCTGCTTCACCACCTTC-3’). Relative TIG1A or
TIG1B mRNA levels were calculated using the following
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-ΔΔCT = 10,000 × 2/([CT of TIG1 in
tissue A]- [CT of GAPDH in tissue A])- ([CT of TIG1 in
colon]- [CT of GAPDH in colon]). All experiments were
performed in triplicate.
Western blot analysis
Total cytosol extracts were prepared in mild lysis buffer
( 2 5m MH E P E S ,p H7 . 5 ,1 5 0m MN a C l ,1 %I g e p a lC A -
630, 10 mM MgCl2, 1 mM EDTA, and 10% glycerol) con-
taining protease inhibitors (20 μg/mL aprotinin and 20
μg/mL phenylmethylsulfonyl fluoride) and phosphatase
inhibitors (2 mM NaF and 1 mM Na3VO4). Proteins (5
to 100 μg) were separated using 10-12% polyacrylamide
gels containing sodium dodecyl sulfate and were then
transferred to polyvinylidene difluoride membranes.
After blocking, membranes were incubated with anti-V5
(Invitrogen), anti-myc (Invitrogen), anti-GRK5 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), or anti-actin
(Sigma) antibody for 12 h at 4°C. Membranes were then
incubated with horseradish peroxidase-conjugated goat
anti-mouse or anti-rabbit antibodies at room temperature
for 1 h. Specific protein bands were developed using
Amersham ECL (Amersham, Bucks, UK). Relative pro-
tein expression levels were quantified by normalising to
actin expression levels.
RNA interference
siRNA oligonucleotides were synthesised by Ambion
(Austin, TX, USA). Three TIG1 siRNAs targeted to
nucleotides 488 to 508 (5’-GUACAAGUUACAUU-
GAUGGtt-3’), 540 to 560 (5’-GUUGUAAAGCAGG
UAAUCCtc-3’), and 596 to 616 (5’-CCAUGAUUAUCA
GGUAUGCtg-3’) were synthesised based on Genbank
accession NM_26963. The TIG1 siRNAs are specific for
both TIG1A and TIG1B isoforms. GRK5 siRNAs tar-
g e t e dt on u c l e o t i d e s4 5 2t o4 7 2( 5 ’-UAACACUCCA
GCCCAGGCCtg-3’), 2158 to 2178 (5’-GAAAUUUCUU
UGAGAAACCtc-3’), and 2406 to 2426 (5’-GCACAGA
AAAUAUACACCCtc-3’) were synthesised according to
Genbank accession NM_005308. The Silencer
® negative
control#1 siRNA (Ambion) was used as a negative con-
trol. Inducible TIG1 or control stable cells were cultured
for 24 h in 6-well plates and then transfected with 30
nM siRNAs using Lipofectamine according to the
instructions provided. After transfection, cells were
incubated in the presence or absence of MFP for 48 h,
and then analysed for growth.
Statistical analysis
Numerical data are shown as mean ± standard deviation
(SD) of triplicates from each independent biological
sample. Cell proliferation, colony formation, and real-
time RT-PCR data were analysed using student’s t test.
P-values less than 0.05 were considered to be
statistically significant. Microarray data were analysed by
one-way ANOVA using GeneSpring GX software.
Results
Expression profiles of both TIG1 isoforms in normal
tissues and colon cancer cell lines
Relative expression levels of TIG1A and TIG1B were
evaluated in normal human tissues and in colon cancer
cell lines using real-time RT-PCR. Both TIG1A and
TIG1B isoforms were expressed at high levels in the
prostate and colon. However, expression was barely
detectable in bone marrow and skeletal muscle (Figure
1A). Compared with normal colon tissue, expression of
both TIG1 isoforms was decreased in all colon cancer
cell lines analysed (Figure 1B). Seven of the cell lines
analysed expressed less than 2 and 11% of normal
TIG1A and TIG1B expression levels, respectively.
Effect of TIG1 isoforms on growth of HCT116 cells
The activities of TIG1A and TIG1B were measured in
HCT116 cells that exhibited high transfection efficiency
Figure 1 TIG1A and TIG1B expression in normal tissues and
colon cancer cell lines. Real time RT-PCR analysis of TIG1A and
TIG1B mRNAs from normal human tissues (A) and colon cancer cell
lines (B). Relative TIG1A and TIG1B mRNA levels were first
normalised to GAPDH levels and then normalised to TIG1A levels in
the normal colon, which was set at 10,000 units. Data represent the
means and SDs from triplicate sample wells.
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TIG1 gene. Ectopically expressed recombinant TIG1A
and TIG1B protein isoforms with the expected molecu-
lar weights of 36.7 and 29.2 kDa, respectively, were
detected in HCT116 cells after transient transfection for
24 h (Figure 2A). The effects of TIG1A and TIG1B
expression on HCT116 cell growth were first analysed
using the WST-1 cell proliferation assay. After 48 h,
HCT116 cell growth was significantly inhibited by 27
and 25% following transient transfection with constitu-
tive TIG1A and TIG1B expression vectors, respectively
(Figure 2B). Similarly, colony formation of HCT116 cells
was significantly suppressed by 63.3 and 89.2% upon
transient transfection with TIG1A and TIG1B expres-
sion vectors, respectively and maintenance in G418-con-
taining media for 8 days (Figure 2C). The effect of TIG1
isoform expression on cell death was also determined by
measuring the release of lactate dehydrogenase in transi-
ently transfected HCT116 cells. Significantly increased
cell death (10.3 to 24.6%) was detected in TIG1B-trans-
fected cells; however, cell death was weakly, but signifi-
cantly, repressed by 5.3 to 12.4% in TIG1A-transfected
cells (Additional file 1).
As production of stable cells constitutively expressing
TIG1A or TIG1B protein was unsuccessful, inducible
TIG1A, TIG1B, and control stable cells were established
Figure 2 Suppression of HCT116 cell growth by TIG1A and TIG1B. (A) Western blot analysis of TIG1 isoforms in transiently transfected
HCT116 cells. Cells were transiently transfected with the indicated expression vectors for 24 h. Expression of TIG1A and TIG1B was detected
using an anti-myc antibody. b-actin expression served as a loading control. (B) Analysis of the effects of TIG1 isoforms on cell proliferation using
the WST-1 cell proliferation assay. Cells were transiently transfected with the indicated constitutive expression vectors for 48 h after which cell
proliferation was measured. Data represent the mean and SD of the percentage of cell proliferation performed in triplicate and are
representative of two independent experiments. (C) The effects of TIG1 isoforms on HCT116 colony formation. Cells were transiently transfected
with the indicated constitutive expression vector, and colony formation was determined. Data represent the mean and SD of percentage colony
formation normalised to the control performed in triplicate. Results are representative of three independent experiments. (D) Analysis of TIG1A
and TIG1B expression in stable cell lines. TIG1A, TIG1B, or control stable clones were incubated in the presence or absence of 5 nM MFP for 0 -
48 h, and expression of TIG1 isoforms was analysed using Western blots analysis and anti-V5 antibody. b-actin expression served as a loading
control. (E) Effects of TIG1 isoform expression on the growth of TIG1 stable cells. TIG1 and control stable clones were incubated with various
concentrations of MFP or vehicle alone for 48 h. Cell proliferation was measured using the WST-1 assay. Data represent the mean and SD of
percentage of cell proliferation performed in triplicate. Results are representative of three independent experiments. *, P < 0.05; **, P < 0.01; ***,
P < 0.001 compared with control stable cells incubated with the indicated concentration of MFP. Ctrl, control.
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which target protein expression is induced by exposure
to MFP. Exposure to 5 nM for 24 to 48 h profoundly
increased expression of TIG1A or TIG1B in respective
TIG1A or TIG1B stable cells, but not the control stable
cells (Figure 2D). Expression of both TIG1A and TIG1B
was induced after exposure to 0.1 - 100 nM MFP for 48
h (data not shown).
To verify that TIG1A and TIG1B expression influ-
enced HCT116 cell growth, proliferation was assessed in
stable clones incubated with various concentrations of
MFP (Figure 2E). Cell proliferation, as determined by
WST-1 cell proliferation assay, was inhibited by MFP
(0.1 - 100 nM) in control stable cells with a maximal
inhibition of 25.4% by 100 nM MFP. Induction of
TIG1A and TIG1B expression by MFP treatment
resulted in a concentration-dependent inhibition of cell
growth in both TIG1A and TIG1B stable cells. When
compared with MFP-treated control stable cells, 29.6
and 22.2% inhibition of cell growth was observed in
TIG1A and TIG1B cells, respectively, incubated with
100 nM MFP for 48 h (Figure 2E). The release of lactate
dehydrogenase as an indicator of cell cytotoxicity in
stable cells exposed to 5 nM MFP for 1 to 2 days was
also analysed; however, no increase in cell death was
observed (data not shown). As 5 nM MFP efficiently
induced expression of recombinant TIG1 isoforms, this
concentration was chosen for microarray analysis to
avoid the identification of genes differentially regulated
by TIG1A or TIG1B in cells exposed to a high concen-
tration of MFP.
Analysis of gene expression profiles in TIG1A and TIG1B
stable cells
To examine the effects of TIG1A and TIG1B on the
gene expression profile of HCT116 cells, stable cells
were incubated with 5 nM MFP for 24 h after which
they were analysed using the human HGU133 Plus 2.0
microarray (Additional file 2). Genes differentially
expressed by greater than two-fold (relative to expres-
sion in control cells) in TIG1A (Additional file 3) or
TIG1B (Additional file 4) stable cells were selected for
analysis. Following induction of TIG1A expression, a
total of 108 and 21 genes were significantly upregulated
or downregulated, respectively (Additional file 3). Simi-
larly, upon induction of TIG1B expression, a total of 41
and 14 genes were upregulated or downregulated,
respectively (Additional file 4). A total of 23 of the upre-
gulated genes and 6 of downregulated genes identified
were detected upon both TIG1A and TIG1B induction
(Figure 3, Additional file 5). Among the 29 genes regu-
lated by both TIG1A and TIG1B isoforms, genes related
to the p53 (wild type p53-induced gene 1 [WIG1] and
small ubiquitin-like modifier 2 [SUMO2]), Wnt
(homeobox B7 [HOXB7]), interleukin (eukaryotic trans-
lation elongation factor 1 epsilon 1 [EEF1E1]), chemo-
kine and cytokine (GRK5 and EEF1E1), and G-protein
coupled receptor (GCPR; GRK5) signaling pathways
were identified.
Upregulation of GRK5 and TCF7 upon TIG1A and TIG1B
expression in HCT116 cells
The Wnt signaling pathway is stimulated by the GPCR
ligand, prostaglandin E2, through enhanced nuclear b-
catenin localisation and b-catenin/TCF-mediated trans-
activation [22]. GRK5 is a member of family proteins
that attenuate GPCR activities. Therefore, GRK5 and
TCF7 were selected for further analysis. Upon exposure
t o5n MM F Pf o r2 4h ,T I G 1 Aa n dT I G 1 Bm R N A s
levels were increased by 107.1- and 29.2-fold, respec-
tively (Figure 4A). Compared with control stable cells,
Figure 3 Microarray analysis of genes differentially regulated
by both TIG1A and TIG1B in HCT116 cells. Control (Ctrl), TIG1A,
and TIG1B stable cells were treated with 5 nM MFP for 24 h. Profiles
of gene expression were then determined using microarray analysis.
After comparing to the gene expression in control cells, genes
upregulated or downregulated by greater than two-fold in both
TIG1A and TIG1B stable cells were subjected to hierarchical
clustering. Average expression was defined by the GeneSpring
®
software. The relative scale of upregulation (red) or downregulation
(green) of gene expression is shown in the right panel.
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Page 7 of 13basal TIG1A and TIG1B mRNA levels in TIG1A and
TIG1B stable cells not exposed to MFP were 166.2- and
37.8-fold higher, respectively. These results suggest the
presence of a weak basal activity of the inducible pro-
moter although basal levels of TIG1 fusion proteins
were not detected by Western blot analysis (Figure 2D
and Figure 4B). Induced expression of TIG1A and
TIG1B by MFP treatment resulted in significantly
increased GRK5 (24.3- and 45.9-fold, respectively) and
TCF7 (16.3- and 35.8-fold, respectively) mRNA levels
(Figure 4A). Basal levels of GRK5 and TCF7 mRNA in
TIG1A and TIG1B stable cells were similar to those in
control cells.
TIG1-mediated regulation of GRK5 and TCF7 protein
expression was examined using Western blot analysis.
No GRK5 protein was detected in MFP-treated control
cells or in TIG1A and TIG1B stable cells in the absence
of MFP treatment. Increased GRK5 protein expression
(65 kDa) was observed in TIG1A and TIG1B stable cells
exposed to 5 nM MFP for 24 to 48 h (Figure 4B). Com-
pared with cells exposed to MFP for 24 h, GRK5 protein
levels were increased by 22 and 75% in TIG1A and
TIG1B stable cells exposed to MFP for 48 h, respec-
tively. Similarly, basal GRK5 protein was not detected in
HCT116 cells (Figure 4C), while GRK5 protein expres-
sion was upregulated in HCT116 cells transiently
Figure 4 Effects of TIG1A and TIG1B on GRK5 and TCF7 expression in HCT116 cells. (A) Real time RT-PCR analysis of gene expression in
inducible stable cells. Stable HCT116 clones were treated with 5 nM MFP for 24 h. Total RNA was extracted and relative levels of the indicated
mRNAs were measured by real-time RT-PCR. Data represent the mean and SD of fold changes in gene expression performed in triplicate after
normalisation to the results obtained from vehicle-treated control stable cells. Results shown are representative of 2 independent experiments.
(B) Western blot analysis of the effects of TIG1 isoforms on GRK5 and TCF7 expression in stable cells. Stable HCT116 clones were treated with 5
nM MFP for 0 to 48 h. Cell lysates were prepared, and expression of TIG1A, TIG1B, GRK5, TCF7 and b-actin was determined by Western blot
analysis. (C) Up-regulation of GRK5 expression in HCT116 cells transiently transfected with a TIG1A expression plasmid. Cells were transiently
transfected with constitutive TIG1A expression vector for 0 to 72 h. TIG1A, GRK5 and b-actin expression from total cellular lysates was
determined by Western blot analysis. Ctrl, control.
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Page 8 of 13transfected with the constitutive TIG1A expression vec-
tor for 24 to 72 h. GRK5 protein levels were increased
(relative to 24 h transfected cell levels) by 58 and 179%
after transfection for 48 and 72 h, respectively. Regard-
less of TCF7 mRNA upregulation, neither TIG1A nor
TIG1B expression influenced TCF7 protein levels after
exposure to MFP for 24 and 48 h (Figure 4B).
Silencing of GRK5 expression decreases TIG1-mediated
suppression of cell growth
To evaluate the role of GRK5 in TIG1-mediated inhi-
bition of HCT116 cell proliferation, RNA interference
was employed. TIG1A stable cells were transiently
transfected with siRNAs specific for both TIG1 iso-
forms or GRK5 and then immediately exposed to 5
nM MFP for 24 h. TIG1A protein levels were reduced
by 53.7% in cells transfected with TIG1 siRNA, while
GRK5 protein levels was reduced by 51.7% in GRK5
siRNA transfected cells, determined by Western blot-
ting analysis (Figure 5A). In control siRNA transfected
TIG1A cells, cellular growth was significantly inhibited
to 70.2% of control levels upon MFP exposure that
induced TIG1A expression. Silencing of TIG1A or
GRK5 expression significantly alleviated TIG1A-
mediated growth suppression to 80 and 88.2% of con-
trol growth, respectively (P <0 . 0 5a n dP <0 . 0 0 1 ,
respectively; Figure 5B). Levels of cell growth in MFP-
treated TIG1A cells transfected with GRK5 siRNA
were slightly higher, but not significant, than that of
cells transfected with TIG1 siRNA.
Both TIG1A and TIG1B isoforms suppressed cell growth
and induced GRK5 expression in SW620 colon cancer
cells
To verify the cell independent effect of TIG1 isoform
expression in colon cancer cells and to evaluate the
effect of TIG1 on cells established from metastatic
lesions, TIGA, TIG1B, and control stable clones were
established from SW620 colon cancer cells derived from
a colon cancer lymph node metastasis. Compared with
HCT116 cells, relative TIG1A mRNA levels were higher
in SW620 cells. However, TIG1B mRNA levels were
lower in SW620 cells (Figure 6A). Upon exposure to 5
nM MFP for 24 to 48 h, enhanced GRK5 protein
expression was accompanied by induced expression of
the TIG1A or TIG1B recombinant protein isoform in
the respective stable, but not in control cells (Figure
6B). Growth in TIG1A and TIG1B stable SW620 cells
was decreased (compared to growth in control stable
cells) by 39 and 39.8%, respectively, upon exposure to
100 nM MFP (Figure 6C). The release of lactate dehy-
drogenase was determined in stable cells exposed to 5
nM MFP for 1 to 2 days; no increase in cell death was
observed (data not shown).
Discussion
TIG1 is a retinoid-inducible tumour suppressor.
Although studies have demonstrated that TIG1B sup-
presses cell growth and invasion, the function of TIG1A
has not been reported. In this study, both TIG1A and
TIG1B were downregulated in colon cancer cell lines,
and their expression suppressed the growth of colon
cancer cells. Various genes involved in cell signaling
pathways associated with the regulation of cellular
growth, differentiation, and apoptosis were differentially
expressed followed the induction of TIG1A or TIG1B
expression in HCT116 cells, while expression of GRK5,
a protein that desensitises GPCR signaling, was upregu-
lated by both TIG1 isoforms. GRK5 silencing alleviated
TIG1A-mediated growth suppression by 60.5%. The
Figure 5 Effects of TIG1A and GRK5 siRNAs on TIG1A-mediated
suppression of HCT116 cell growth. (A) TIG1A cells were
transfected with the indicated siRNA after which they were
immediately incubated with MFP (5 nM) for 24 h. Expression of
TIG1A, GRK5, and actin was examined by Western blot analysis
using anti-myc, anti-GRK5, and anti-actin antibodies, respectively. (B)
Inducible TIG1A stable cells were plated in triplicate overnight, and
then transfected with the indicated siRNA, and incubated in the
presence or absence of 5 nM MFP for 48 h. Cell proliferation was
measured using the WST-1 method. Relative levels of cell growth
were normalised to that of control siRNA transfected cells without
MFP treatment. *, P < 0.05 and ***, P < 0.001.
Wu et al. BMC Cancer 2011, 11:175
http://www.biomedcentral.com/1471-2407/11/175
Page 9 of 13extent of growth reversion and inhibition of GRK5
expression was largely similar in TIG1A expressing cells
transfected with GRK5 siRNA, suggesting that GRK5
plays a pivotal role in TIG1-mediated growth inhibition
of HCT116 colon cancer cells.
Loss of TIG1 expression through promoter DNA hyper-
methylation occurs in many tumour tissues [5-11], sug-
gesting that the loss of TIG1 provides a survival advantage
to tumour cells. This notion is supported by findings from
this and previous studies [2,7,10] demonstrating the
growth and invasion suppressive activities of TIG1 in
prostate, endometrial, nasopharyngeal, and colon cancer
cells. The strong growth suppressive activities of TIG1 are
also supported by the unsuccessful establishment of
TIG1B stable cells from endometrial cancer cells observed
previously [10]. Similarly, we have failed to establish con-
stitutive TIG1A and TIG1B stable clones from CC-M2,
SW620, and HCT116 colon cancer cells. Therefore, the
inducible GeneSwitch system, with reported low basal
expression, was used in our study [18,20].
In our study, both TIG1 isoforms exhibited growth
suppressive activities in transiently transfected HCT116
cells and TIG1-expressing stable HCT116 and SW620
cells. However, only TIG1B was shown to induce cell
death of transiently transfected HCT116 cells. This may
explain the greater inhibition of colony formation in
TIG1B-transfected HCT116 cells, compared with in
TIG1A transfected cells. In inducible stable cells, MFP
alone exhibited growth suppressive activity in both
HCT116 and SW620 cells. This may be related to the
relatively weak (22.2 to 39.8%) TIG1-mediated growth
inhibition of stable TIG1A and TIG1B expressing cells.
MFP, a competitive progesterone receptor antagonist,
serves as progesterone receptor or estrogen receptor
Figure 6 Effect of stable TIG1 expression on GRK5 expression and cell growth of SW620 colon cancer cells. (A) Real time RT-PCR analysis
of TIG1A and TIG1B mRNA levels from HCT116 and SW620 colon cancer cell lines. (B) GRK5 expression in inducible TIG1 stable cells established
from SW620 cells. Control or inducible TIG1A and TIG1B stable cells were plated overnight and then incubated with 5 nM MFP for 0 to 48 h.
Expression of GRK5, TIG1 isoforms, and actin were analysed by Western blotting. (C) Effects of TIG1 isoform expression on SW620 cell growth.
Inducible TIG1 and control stable clones were plated in triplicate overnight and then incubated with the indicated concentrations of MFP for 48
h. Cell proliferation was measured using the WST-1 method. Data represent the mean and SD of the percentage of cell proliferation performed
in triplicate. *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared with control stable cells incubated with the indicated concentration of MFP. Ctrl,
control.
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Page 10 of 13agonist in the absence of progesterone [23] or estrogen
[24], respectively. Colon cancer tissues express estrogen
and progesterone receptors [25]. Several studies have
demonstrated that the estrogen receptor may play a role
in the growth inhibition of colon cancer cells in vitro
[26] and in vivo [27]. This may explain the weak growth
suppressive activity of MFP on stable control HCT116
and SW620 cells. The weak growth suppressive activity
of MFP on colon cancer cells may mask the growth sup-
pressive and/or cell death inducing activities of the
TIG1A and TIG1B isoforms on colon cancer cells. This
may be related to the lack of cell death induction in
both stable TIG1 cells established from HCT116 and
SW620 cells followed by TIG1A or TIG1B expression
upon MFP exposure. We also examined cell cycle pro-
gression in stable HCT116 cells and found that TIG1A,
but not TIG1B, significantly decreased the progression
of cells from the G1 phase to the S phase in MFP (5
nM)-treated, serum-deprived stable HCT116 cells re-sti-
mulated with complete medium for 12 h (Additional file
6). Therefore, TIG1 isoforms may induce growth sup-
pression of colon cancer cells through multiple
mechanisms.
GRK5 is a serine/threonine kinase and is ubiquitously
expressed in most tissues [28], suggesting the physiolo-
gical significance of this protein. GRK5 desensitises the
activation of the GPCR signaling pathway by inducing
the phosphorylation of agonist-bound GPCR, which in
turn leads to uncoupling of the receptor from the G
protein and subsequent inhibition of signaling [19]. In
addition to inhibiting GPCR-mediated physiological pro-
cesses, the activity of GRK5 is also mediated through
non-GPCR pathways. For example, GRK5 directly phos-
phorylates the PPPSP motifs on the single transmem-
brane low density lipoprotein receptor-related protein 6
(LRP6) and stimulates Wnt/LRP6 signaling [29]. GRK5
i sa l s oe x p r e s s e di nt h en u c l e u sa n df u n c t i o n sa sa
kinase for p53 [30] and histone deacetylase [31]. Further,
GRK5-mediated phosphorylation increases histone dea-
cetylase activity [32] and promotes p53 degradation [30].
Finally, GRK5 binds IBa, inducing nuclear accumula-
tion and leading to suppression of NFB-mediated
transactivation and cell growth in vitro and in vivo
[33,34].
In the present study, we observed partial, but signifi-
cant, reversion of TIG1-mediated growth suppression in
TIG1A-expressing HCT116 cells after transfection with
TIG1 and GRK5 siRNA. The partial reversion of TIG1-
mediated growth inhibition may due to incomplete
knockdown of TIG1A and GRK5 protein expression
(see Figure 5A). The fact that knockdown of GRK5
expression using GRK5 siRNAs significantly alleviated
TIG1A-mediated growth inhibition suggests that GRK5
plays an important role in regulating TIG1A-mediated
growth in HCT116 cells. GRK5 participates in multiple
signaling pathways at the plasma membrane and nucleus
(as described above), which may explain the slightly
higher, although not statistically significant, reversion of
TIG1A-mediated growth suppression in TIG1A expres-
sing cells using GRK5 siRNA compared with the cells
transfected with TIG1A siRNA. Elevated PGE2 levels,
which lead to enhanced GPCR signaling, play an impor-
tant role in colorectal carcinogenesis [35]. Whether the
e f f e c t so fG R K 5o nT I G 1 A - m ediated cellular changes
are related to inhibition of GPCR, non-GPCR, or both
pathways merits further investigation.
In TIG1A-expressing cells, genes participating in p53
(seven in absentia homolog 1 [SIAH1]), Wnt (protein
phosphatase 3 [PPP3CA], TCF7, AT rich interactive
domain 1A [ARID1A], SIAH1, and Nuclear factor of
activated T-cells, cytoplasmic 1 [NFATC1]), chemokine
and cytokine (NFATC1, Rho-associated, coiled-coil con-
taining protein kinase 2 [ROCK2], signal transducer and
activator of transcription 2 [STAT2], and forkhead box
D1 [FOXD1]), and GPCR (guanine nucleotide binding
protein, alpha stimulating [GNAS]) signaling pathways
were differentially upregulated. In addition, genes parti-
cipating in angiogenesis (fibroblast growth factor recep-
t o r s2a n d3[ F G F R 2a n dF G F R 3 ] ,p r o t e i nt y r o s i n e
phosphatase, non-receptor type 6 [PTPN6], STAT2, and
platelet-derived growth factor C [PDGFC]) and fibro-
blast growth factor signaling (FGFR2, PPP2R2C and
FGFR3) were specifically upregulated. Furthermore,
most signal pathways involving genes differentially regu-
lated by TIG1B were similarly expressed in TIG1A
expressing cells. Although TIG1 proteins belong to the
latexin protein family, only the TIG1A isoform contains
the complete latexin domain that spans amino acids 51
to 276. The TIG1B isoform contains only the N-term-
inal portion of the latexin domain. A difference in the
carboxyl terminus between the 2 TIG1 isoforms may
explain why TIG1A differentially regulated more genes
associated with cellular growth, apoptosis, and protein
transportation and secretion than TIG1B. Despite the
structural difference at the carboxyl terminus, both
TIG1 isoforms suppressed cell growth. Thus, the N-
terminal 224 amino acid fragment of TIG1A may under-
lie growth suppressive activity.
T h ep r e s e n ts t u d ya l s od e m o n s t r a t e dt h a tT I G 1 Ab u t
not TIG1B delayed progression from the G1 phase to
the S phase in MFP-treated, serum-starved stable
HCT116 cells after re-exposure to serum containing
medium for 12 h (Additional file 6). This result suggests
that the growth-related activities of the TIG1 protein
may also reside in the carboxyl terminus region of the
TIG1A protein, which is supported by the differential
expression of a larger number of genes in TIG1A-
expressing stable cells compared with TIG1B-expressing
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Page 11 of 13cells. Further analysis of the correlation between protein
structure and biological activities of TIG1 will be impor-
tant to elucidate the function of TIG1 proteins.
Conclusion
In conclusion, we have demonstrated decreased expres-
sion of both TIG1 isoforms in colon cancer cell lines
compared with expression in normal tissue. In addition,
both TIG1 isoforms similarly suppressed colon cancer
cell growth. Our findings suggest that TIG1-mediated
growth suppression of colon cancer cells is mediated, at
least in part, through GRK5. Further analysis of the
genes differentially regulated by TIG1A and TIG1B
expression will expand our understanding of the mole-
cular mechanism of TIG1-mediated growth suppression
in cancer cells.
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